Fig. 7: Anti-tumor activity of vepafestinib against KIF5B–RETG810R-driven allograft tumors.
a, Animals bearing Ba/F3 KIF5B–RETWT allograft tumors were treated with vehicle (n = 6) or the indicated dosages of vepafestinib (n = 6). b, Animals bearing Ba/F3 KIF5B–RETWT tumors were treated with a single dose of 50 mg per kg vepafestinib, and then tumors were collected at the indicated time points after inhibitor administration for western blotting analysis. Representative immunoblots on which two tumors from each condition were examined are shown. c,d, Mice bearing Ba/F3 KIF5B–RETG810R xenograft tumors were administered vepafestinib (n = 5), selpercatinib (n = 5), pralsetinib (n = 5) or vehicle (n = 5) orally at the indicated dosages BID for 14 d (days 1–14) after grouping. e, Mice bearing Ba/F3 KIF5B–RETG810R allograft tumors were administered 10 or 30 mg per kg vepafestinib, selpercatinib or pralsetinib, and then tumors were collected 1 h later for western blot analysis. Representative immunoblots on which two tumors from each condition were examined are shown. Tumor volume for each dosing group was measured and shown as mean ± s.e.m. Statistical analysis was performed using Dunnett’s test (vehicle versus vepafestinib, selpercatinib or pralsetinib) or Tukey’s test (vepafestinib versus selpercatinib or pralsetinib), and P values are shown. All tests were two sided. GAPDH was used as a loading control in b,e.
